Toshihiro Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Toshihiro Kimura has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Kiyoshi Yoshino
Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kitakyushu, Japan
1 shared publication - Masami Fujita
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka, Japan
1 shared publication - Tadashi Kimura
Sakai City Medical Center, Sakai, Japan
1 shared publication - Takashi Miyatake
Department of Obstetrics and Gynecology, Osaka Police Hospital, Tennoji-ku, Osaka 543-0035, Japan
1 shared publication - Takayuki Enomoto
Osaka University Graduate School of Medicine
1 shared publication - Yutaka Ueda
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
1 shared publication
Latest Publications
- Open Access
Serum Biomarkers for Early Detection of Gynecologic Cancers
Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28–85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation.
Open AccessSerum Biomarkers for Early Detection of Gynecologic Cancers
Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28–85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation.